Dihexa (PNB-0408) (N-hexanoic-Tyr-Ile-(6)-amino hexanoic amide) is an oral active, blood-brain barrier-permeable angiotensin IV analogue. Dihexa (PNB-0408) is a synthetically derived Angiotensin IV analog that is blood-brain barrier permeable, stable, and orally bioavailable[1].
Under Dihexa (PNB-0408) stimulation, the hepatocyte growth factor (HGF)/c-Met receptor system can induce dendritic dendrites and synaptogenesis[2]. The hepatoblasts were differentiated into HLCs by Dihexa and dexamethasone[3]. Dihexa(PNB-0408)( 0.1 μM) combining Vitamin C, and Forskolin (VDF) could substitute growth factors to induce hepatic specification[4]. Dihexa (PNB-0408) at both concentrations(10-10 M and 10-12 M; 30 minutes; room temperature) markedly augmented the capacity of HGF to activate c-Met[5].
Dihexa (PNB-0408) (1.44/2.88 mg/kg ;i.g.; 3 months) restored AngIV decline in APP/PS1 mice, saved the cognitive function of mice, improved neuronal loss in mice and reduced neuroinflammation and inhibited glial activation in the mouse brain[6]. Dihexa (PNB-0408)(10-6M-10-13M;30 min) protects lateral line hair cells from aminoglycoside ototoxicity. Dihexa does not alter the entry of aminoglycosides into hair cells but rather attenuates cell death through an HGF-dependent signaling mechanism [7]. Dihexa (PNB-0408) (2-4mg/kg;b.wt.;16 weeks) is promising candidates for adjunct therapies to promote limb functional recovery after surgical nerve repair, and have implications in peripheral nerve injury and limb transplantation[8].
References:
[1]. McCoy AT, Benoist CC, et,al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013 Jan;344(1):141-54. doi: 10.1124/jpet.112.199497. Epub 2012 Oct 10. PMID: 23055539; PMCID: PMC3533412.
[2]. Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2015;45(4):985-1000. doi: 10.3233/JAD-142814. PMID: 25649658.
[3]. Mathapati S, Siller R, et,al. Small-Molecule-Directed Hepatocyte-Like Cell Differentiation of Human Pluripotent Stem Cells. Curr Protoc Stem Cell Biol. 2016 Aug 17;38:1G.6.1-1G.6.18. doi: 10.1002/cpsc.13. PMID: 27532814.
[4]. Pan T, Wang N, et,al. Efficiently generate functional hepatic cells from human pluripotent stem cells by complete small-molecule strategy. Stem Cell Res Ther. 2022 Apr 11;13(1):159. doi: 10.1186/s13287-022-02831-1. PMID: 35410439; PMCID: PMC8996222.
[5]. Benoist CC, Kawas LH, et,al.The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402. doi: 10.1124/jpet.114.218735. Epub 2014 Sep 3. PMID: 25187433; PMCID: PMC4201273.
[6]. Sun X, Deng Y,et,al. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021 Nov 11;11(11):1487. doi: 10.3390/brainsci11111487. PMID: 34827486; PMCID: PMC8615599.
[7]. Uribe PM, Kawas LH, et,al. Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure. Front Cell Neurosci. 2015 Jan 28;9:3. doi: 10.3389/fncel.2015.00003. PMID: 25674052; PMCID: PMC4309183.
[8]: Weiss JB, Phillips CJ, et,al.Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies. Ann Med Surg (Lond). 2021 Oct 8;71:102917. doi: 10.1016/j.amsu.2021.102917. PMID: 34703584; PMCID: PMC8524106.
Dihexa (PNB-0408)(N-己酸-Tyr-Ile-(6)-氨基己酰胺)是一种具有口服活性、可透过血脑屏障的血管紧张素 IV 类似物。 Dihexa (PNB-0408) 是一种合成衍生的血管紧张素 IV 类似物,具有血脑屏障渗透性、稳定性和口服生物利用度[1]。
在 Dihexa (PNB-0408) 刺激下,肝细胞生长因子 (HGF)/c-Met 受体系统可诱导树突状树突和突触发生[2]。 Dihexa和地塞米松[3]将成肝细胞分化为HLCs。 Dihexa(PNB-0408)( 0.1 μM) 结合维生素 C 和 Forskolin (VDF) 可以替代生长因子诱导肝脏规范化[4]。 Dihexa (PNB-0408) 在两个浓度(10-10 M 和 10-12 M;30 分钟;室温)下显着增强 HGF 激活 c-Met[5] 的能力。
Dihexa (PNB-0408)(1.44/2.88 mg/kg ;i.g.;3 个月)恢复 APP/PS1 小鼠的 AngIV 下降,挽救小鼠的认知功能,改善小鼠的神经元丢失并减少神经炎症并抑制神经胶质细胞激活在小鼠大脑中[6]。 Dihexa (PNB-0408)(10-6M-10-13M;30 分钟)保护侧线毛细胞免受氨基糖苷类的耳毒性。 Dihexa 不会改变氨基糖苷类药物进入毛细胞,而是通过 HGF 依赖性信号机制[7] 减弱细胞死亡。 Dihexa (PNB-0408)(2-4mg/kg;b.wt.;16 周)有望成为辅助疗法的候选药物,以促进手术神经修复后的肢体功能恢复,并对周围神经损伤和肢体移植有影响 [8].
















